Aimmune Therapeutics (AIMT) Misses Q4 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2015 Financial Results and Provides Corporate Update
March 3, 2016 4:05 PM ESTCompany Began 2016 with Approximately $200 Million in Cash and Investments and Its Phase 3 PALISADE Trial Underway for Peanut Allergic Patients
Late-Breaker Presentation on New AR101 Phase 2 Data This Sunday at AAAAI
Conference Call and Webcast Today at 5 p.m. Eastern Time / 2 p.m. Pacific Time
BRISBANE, Calif.--(BUSINESS WIRE)-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing CODIT (characterized oral desensitization immunotherapy) treatments for life-threatening food allergies, today announced financial results for the fourth quarter and full year 2015 and provided a corporate... More
